Phase 3 Readout
OLMA: Phase 3 Topline: A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment
February 29, 2028 · op-1250. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- February 29, 2028
- Company
- Olema Pharmaceuticals, Inc. (OLMA)
- Drug
- op-1250
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment
- Drug
- op-1250
- Indication
- Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer